A new study has found that the clot-dissolving drug alteplase can significantly improve stroke recovery even when given up to ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

A recent study from Chinese researchers reveals that alteplase, a clot-busting medication, can significantly improve recovery outcomes for stroke patients, increasing chances of recovery by over 50% ...

A team of Chinese researchers has found that clot-dissolving medication – alteplase – can be key to improving stroke patients' recovery by more than 50 per cent. The team from Zhejiang University, ...

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...

Alteplase improves stroke recovery by over 50% when given up to 24 hours after symptom onset, offering hope for patients with ...

In a randomized clinical trial, giving the clot-busting medication alteplase up to 24 hours after stroke symptoms first appeared increased the odds of better recovery by 50% compared to those who ...

In a randomized clinical trial in China, giving the clot-busting medication alteplase up to 24 hours after stroke symptoms ...

“These findings should reassure both clinicians and patients that mt-sDNA testing can be performed safely without stopping anticoagulant or antiplatelet therapy,” Garg told Healio. “From a ...

Introduction: In patients with large vessel occlusion stroke of the anterior circulation who are treated with mechanical thrombectomy (MT) and intravenous thrombolysis (IVT), there is no clear ...

HealthDay News — Heart disease continues to be a leading cause of death, according to a report from the American Heart Association published online in Circulation. Seth S. Martin, MD ...

The combination of clopidogrel and warfarin therapy is associated with an increased incidence of major bleeding when compared with monotherapy alone. Use of combination antiplatelet and ...